Previous close | 1.0600 |
Open | 1.0700 |
Bid | 1.0700 x 6000 |
Ask | 1.1000 x 1300 |
Day's range | 1.0600 - 1.1300 |
52-week range | 0.8500 - 5.5300 |
Volume | |
Avg. volume | 8,341,045 |
Market cap | 208.161M |
Beta (5Y monthly) | 0.87 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Detailed Analysis of Financial Performance and Future Outlook
bluebird (BLUE) beats sales estimates in the first quarter on increased Zynteglo product revenues. The company is on track with the ongoing launch of its gene therapies.
bluebird bio, Inc. (NASDAQ:BLUE) Q4 2023 Earnings Call Transcript March 26, 2024 bluebird bio, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome to bluebird bio Fourth Quarter and 2023 Annual Results Conference Call. At this […]